BRANFORD: Thetis Pharmaceuticals, a research level bio-tech founded in 2011 by by ex-Pfizer R&D executives and healthcare investors, announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health for $2.3 million.. The grant will support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis.
|Thetis CEO Mathias: "A fundamentally new approach."|
Gary Mathias, Co-founder and Chief Executive Officer, said, “TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system. The grant will support the advancement of this promising, potential new therapy into the clinic.”
Preclinical efficacy studies are being conducted in collaboration with Dr. Daniel Rosenberg, Professor of Medicine at the University of Connecticut. Dr. Rosenberg commented: “TP-317 delivers a natural bioactive lipid known as Resolvin E1 that regulates the inflammatory response.”
Thetis is funded by Connecticut Innovations, Inc. and is a member of the Technology Incubation Program at University of Connecticut Health.